Chengyu Liang

Title: Chengyu Liang: Innovator in Hepatitis C Research

Introduction

Chengyu Liang is a prominent inventor based in Stony Brook, NY (US). He has made significant contributions to the field of virology, particularly in the study of Hepatitis C Virus (HCV). His innovative work has led to the development of a replicon that plays a crucial role in identifying antiviral compounds.

Latest Patents

Chengyu Liang holds a patent for an "Efficient hepatitis C virus replicon and its use in identifying antiviral compounds." This invention provides a Hepatitis C Virus (HCV) replicon that efficiently replicates in eukaryotic cells. The replicon includes a nucleic acid sequence encoding subgenomic fragments of HCV of any genotype, which confer the ability to replicate. Additionally, it features a nucleic acid sequence encoding an acetyl transferase selectable marker, such as puromycin. The invention also includes eukaryotic cell lines that contain the HCV replicon, which efficiently replicate in these cells. Furthermore, it offers screening methods for identifying candidate compounds that inhibit the propagation of HCV. Chengyu Liang has 1 patent to his name.

Career Highlights

Chengyu Liang is affiliated with the State University of New York, where he conducts his research and development work. His contributions to the field of virology have been recognized and have paved the way for advancements in antiviral therapies.

Collaborations

Chengyu Liang has collaborated with notable researchers, including Eckard Wimmer and Sung Key Jang. Their combined efforts have furthered the understanding of Hepatitis C and the development of effective treatments.

Conclusion

Chengyu Liang's innovative work in the field of Hepatitis C research exemplifies the importance of scientific inquiry and collaboration. His contributions have the potential to significantly impact the treatment of viral infections.